Literature DB >> 19224316

The management of amyotrophic lateral sclerosis.

Julie Phukan1, Orla Hardiman.   

Abstract

The terms amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND) refer to a condition characterized by motor system degeneration with relative preservation of other pathways. Although there have been advances in symptomatic treatment, ALS remains an incurable condition. Advances in ALS management prolong survival but simultaneously raise challenging ethical dilemmas for physicians, patients and their families. Here, we review current practice in the management of ALS including pharmacological treatment, nutritional management, respiratory care, and evolving strategies in the management of cognitive impairment.

Entities:  

Mesh:

Year:  2009        PMID: 19224316     DOI: 10.1007/s00415-009-0142-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  78 in total

1.  Occurrence of amyotrophic lateral sclerosis among Gulf War veterans.

Authors:  Carmel Armon
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

Review 2.  Ethnic variation in the incidence of ALS: a systematic review.

Authors:  Simon Cronin; Orla Hardiman; Bryan J Traynor
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

3.  Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders.

Authors:  Julian Grosskreutz; Thomas Peschel; Alexander Unrath; Reinhard Dengler; Albert C Ludolph; Jan Kassubek
Journal:  Amyotroph Lateral Scler       Date:  2008-08

4.  The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study.

Authors:  K R Chaudhuri; S Crump; S al-Sarraj; V Anderson; J Cavanagh; P N Leigh
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

5.  Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS.

Authors:  S C Bourke; P J Shaw; G J Gibson
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

6.  Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis.

Authors:  G Miscio; F Pisano; G Mora; L Mazzini
Journal:  Clin Neurophysiol       Date:  1999-05       Impact factor: 3.708

7.  Outcome of ventilatory support for acute respiratory failure in motor neurone disease.

Authors:  M D Bradley; R W Orrell; J Clarke; A C Davidson; A J Williams; D M Kullmann; N Hirsch; R S Howard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

Review 9.  Electrodiagnostic criteria for diagnosis of ALS.

Authors:  Mamede de Carvalho; Reinhard Dengler; Andrew Eisen; John D England; Ryuji Kaji; Jun Kimura; Kerry Mills; Hiroshi Mitsumoto; Hiroyuki Nodera; Jeremy Shefner; Michael Swash
Journal:  Clin Neurophysiol       Date:  2007-12-27       Impact factor: 3.708

10.  Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.

Authors:  Felix Geser; Nicholas J Brandmeir; Linda K Kwong; Maria Martinez-Lage; Lauren Elman; Leo McCluskey; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2008-05
View more
  9 in total

1.  Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2018-01

2.  Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients.

Authors:  Maud Maessen; Jan H Veldink; Leonard H van den Berg; Henrike J Schouten; Gerrit van der Wal; Bregje D Onwuteaka-Philipsen
Journal:  J Neurol       Date:  2010-02-11       Impact factor: 4.849

3.  Validating population-based registers for ALS: how accurate is death certification?

Authors:  Loraine Yeo; Catherine Lynch; Orla Hardiman
Journal:  J Neurol       Date:  2010-02-12       Impact factor: 4.849

4.  Bone marrow transplantation in hindlimb muscles of motoneuron degenerative mice reduces neuronal death and improves motor function.

Authors:  Diego Pastor; Mari Carmen Viso-León; Arancha Botella-López; Jesus Jaramillo-Merchan; Jose M Moraleda; Jonathan Jones; Salvador Martínez
Journal:  Stem Cells Dev       Date:  2013-02-13       Impact factor: 3.272

5.  Structural and functional analysis of human SOD1 in amyotrophic lateral sclerosis.

Authors:  Lorenna Giannini Alves Moreira; Livia Costa Pereira; Priscila Ramalho Drummond; Joelma Freire De Mesquita
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 6.  Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms.

Authors:  Taiwo Olayemi Elufioye; Tomayo Ireti Berida; Solomon Habtemariam
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-22       Impact factor: 2.629

7.  Relationship between Dietary Total Antioxidant Capacity and the Prognosis of Amyotrophic Lateral Sclerosis.

Authors:  Jihyun Eom; Bugyeong Son; Seung Hyun Kim; Yongsoon Park
Journal:  Nutrients       Date:  2022-08-10       Impact factor: 6.706

Review 8.  ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease.

Authors:  Elizabeth B Moloney; Fred de Winter; Joost Verhaagen
Journal:  Front Neurosci       Date:  2014-08-14       Impact factor: 4.677

9.  Relationship between Dietary Fiber Intake and the Prognosis of Amytrophic Lateral Sclerosis in Korea.

Authors:  Haelim Yu; Seung Hyun Kim; Min-Young Noh; Sanggon Lee; Yongsoon Park
Journal:  Nutrients       Date:  2020-11-07       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.